Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 235,529,878 papers from all fields of science
Search
Sign In
Create Free Account
EZH2 protein, human
Known as:
ENX-1 protein, human
, Histone-Lysine N-Methyltransferase EZH2
, ENX-1
Expand
Histone-lysine N-methyltransferase EZH2 (746 aa, ~85 kDa) is encoded by the human EZH2 gene. This protein is involved in the regulation of chromatin…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
18 relations
DNA-Binding Proteins
DOT1L wt Allele
EZH2 gene
EZH2 wt Allele
Expand
Broader (1)
Enhancer of Zeste Homolog 2 Protein
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
LncRNA CACS15 accelerates the malignant progression of ovarian cancer through stimulating EZH2-induced inhibition of APC.
Yanhong Liu
,
J. Sun
,
+4 authors
Q. Xiang
American journal of translational research
2019
Corpus ID: 208143074
To elucidate the potential function of lncRNA CACS15 in the progression of ovarian cancer (OC) and its underlying mechanism…
Expand
2019
2019
EZH 2 plays a crucial role in ischemia / reperfusion-induced acute kidney injury by regulating p 38 signaling
Liang
,
Huang
,
Liao
,
Zhang
,
Liu
2019
Corpus ID: 102483257
Objective and design Renal ischemia–reperfusion (IR)-induced acute kidney injury (AKI) remains a major challenge in clinic. The…
Expand
2017
2017
Elevated Metabolic Activity on 18F-FDG PET/CT Is Associated with the Expression of EZH2 in Non-small Cell Lung Cancer.
G. Toyokawa
,
K. Takada
,
+10 authors
Y. Maehara
Anticancer Research
2017
Corpus ID: 42051253
BACKGROUND/AIM Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that is deeply involved in the pathogenesis of…
Expand
2017
2017
Abstract 5060: Activity of the EZH2 inhibitor tazemetostat as a monotherapy and in combination with multiple myeloma therapies in preclinical models
Allison E. Drew
,
Vinny Motwani
,
+6 authors
S. Ribich
2017
Corpus ID: 79762421
The EZH2 inhibitor tazemetostat (EPZ-6438) is currently being evaluated in phase 2 clinical trials for the treatment of non…
Expand
2017
2017
Effect of EZH 2 Inhibition on Colorectal Cancer Cells : an In Vitro Study
Farnia Ghafouri Sabzevari
,
Madjid Momeni-Moghaddam
,
F. Farassati
,
A. Rad
2017
Corpus ID: 55170980
Recently, the epigenetic modifications have been recognized as a regulator of gene expression in various cancers. EZH2 gene is…
Expand
2016
2016
Diagnostic Discrimination of Fine Needle Aspiration Specimens of Hepatic Nodules using Immunohistochemical Expression of GPC3 and EZH2
S. Elbasateeny
,
Taiseer R. Ibrahim
,
Abdelmonem Awad Hegazy
,
N. Shaheen
2016
Corpus ID: 56237017
The goal of the present study was to examine the immunohistochemical expression of Glypican-3 (GPC3) and Enhancer of zeste…
Expand
2016
2016
FoxC 1 promotes osteosarcoma cell proliferation and metastasis through the activation of EZH 2
Z. Qiu
,
Zhong Dan
,
Xiaoming Che
2016
Corpus ID: 4839556
The underlying mechanism of osteosarcoma proliferation, migration and invasion remains to be elucidated. Here, we set out to…
Expand
2016
2016
MiR-137 regulates the proliferation and invasion of glioma cells through EZH 2 / Wnt / β-catenin signaling pathway
Zong Wang
,
Jiangwei Yuan
,
Yang Yang
,
Li Li
,
Jidong Liu
,
Ying Wang
2016
Corpus ID: 43954488
MicroRNAs (miRNAs) play critical roles in tumor development. In the present study, we explored the role of miR-137 in glioma…
Expand
2014
2014
Osteopontin Promotes EZH2 Expression and Tumor Progression in Nasopharyngeal Carcinoma
R. Ma
,
Xi Luo
,
+4 authors
Huabin Li
ORL
2014
Corpus ID: 23800242
Objective: To evaluate the possible mechanism of osteopontin (OPN) in the tumor progression of nasopharyngeal carcinoma (NPC…
Expand
2007
2007
Anti-leukemia activity of histone deacetylase (HDAC) inhibitor LBH589 involves depletion of EZH2 and DNA methyltransferase (DNMT) 1 through disruption of their chaperone association with heat shock…
K. Bhalla
,
W. Fiskus
,
+4 authors
P. Atadja
2007
Corpus ID: 74561937
10501 Background: LBH589 is a hydroxamate pan-HDAC inhibitor (HA-HDI) that also inhibits HDAC6, which induces acetylation of…
Expand